Company

OliX Pharmaceuticals, Inc.

OliX Pharmaceuticals develops RNA interference therapeutics for a range of diseases.

About

Founded in 2010 in South Korea, OliX Pharmaceuticals develops RNAi therapeutics using siRNA, asiRNA, cp-asiRNA and GalNAc-asiRNA platforms. Its pipeline includes programs for hypertrophic scars, androgenic alopecia, macular degeneration, MASH, obesity and other cardiometabolic disorders. In June 2026, BOLD and Weiss Asset Management LP participated in a PIPE transaction that raised approximately KRW 110 billion.

5Funding rounds

13Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in